scispace - formally typeset
S

Schahram Akbarian

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  241
Citations -  20078

Schahram Akbarian is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Chromatin & Epigenetics. The author has an hindex of 72, co-authored 209 publications receiving 17366 citations. Previous affiliations of Schahram Akbarian include Harvard University & University of York.

Papers
More filters
Journal ArticleDOI

Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice

TL;DR: The results indicate that the role of MECp2 is not restricted to the immature brain, but becomes critical in mature neurons, and that Mecp2 deficiency in these neurons is sufficient to cause neuronal dysfunction with symptomatic manifestation similar to Rett syndrome.
Journal ArticleDOI

Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.

TL;DR: The prefrontal cortex of schizophrenics shows reduced expression for GAD in the absence of significant cell loss, bringing about an activity-dependent down-regulation associated with the functional hypoactivity of the DLPFC and implying that overall cortical neuronal migration had not been compromised in development.
Journal ArticleDOI

Altered Distribution of Nicotinamide-Adenine Dinucleotide Phosphate—Diaphorase Cells in Frontal Lobe of Schizophrenics Implies Disturbances of Cortical Development

TL;DR: Findings are consistent with a disturbance of the subplate during development in which the normal pattern of programmed cell death is compromised and accompanied by a defect in the normal orderly migration of neurons toward the cortical plate, likely to have serious consequences for the establishment of anormal pattern of cortical connections leading to a potential breakdown of frontal lobe function in schizophrenics.
Journal ArticleDOI

Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse

TL;DR: The histone deacetylase inhibitor SB exerts antidepressant-like effects in the mouse and the therapeutic benefits and molecular actions of histone modifying drugs, including co-treatment with SSRIs and other newer generation antidepressant medications, warrant further exploration in experimental models.